logo
Twitter
Discord
Email
logo
Accuray Incorporated

Accuray Incorporated

NASDAQ•ARAY
CEO: Ms. Suzanne Winter M.B.A.
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2007-02-08
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
Contact Information
1240 Deming Way, Madison, WI, 53717-1954, United States
608-824-2800
www.accuray.com
Market Cap
$92.46M
P/E (TTM)
-5.0
33.6
Dividend Yield
--
52W High
$2.95
52W Low
$0.78
52W Range
2%
Rank68Top 98.2%
1.3
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q1 2026 Data

Revenue

$93.94M-7.49%
4-Quarter Trend

EPS

-$0.18+355.70%
4-Quarter Trend

FCF

$8.36M-199.31%
4-Quarter Trend

2026 Q1 Earnings Highlights

Key Highlights

Service Revenue Increased Services revenue reached $56.8M USD for the quarter, marking a 7% increase compared to prior year period.
Product Sales Decreased Product revenue fell sharply to $37.2M USD, a 23% decrease driven by lower shipments volume to China.
Positive Operating Cash Flow Net cash provided by operating activities totaled $12.2M USD for the three months ended September 30, 2025.
Strategic Transformation Announced Company announced major organizational transformation in October 2025, appointing Stephen La Neve as new CEO.

Risk Factors

Macroeconomic Headwinds Persist Inflation, supply chain issues, and logistics costs expected to adversely affect gross margins through at least fiscal year 2026.
China Sales Volume Impacted Uncertainty regarding U.S.-China trade tariffs expected to decrease China sales volume through at least first half fiscal 2026.
Deteriorating Profitability Metrics Gross profit dropped 23% to $26.5M USD; net loss widened to $(21.7M) USD for the quarter.
Debt Covenants Compliance Risk Compliance with Financing Agreement covenants depends on future performance; failure risks debt acceleration and foreclosure.

Outlook

Liquidity Position Adequate Current cash balance and debt facilities sufficient to fund operations for at least the next twelve months period.
Restructuring Cost Accrual Recorded $1.5M restructuring charge for workforce reduction; remaining accrual of $1.9M expected to be paid in fiscal 2026.
New Financing Agreement Secured new five-year Financing Agreement providing $150M term loan and $20M delayed draw facility in June 2025.
Tax Law Changes Evaluation Evaluating impact of new federal tax legislation enacted July 2025, including changes to R&D expense capitalization rules.

Peer Comparison

Revenue (TTM)

Accuray IncorporatedARAY
$450.90M
+1.5%
Sight Sciences, Inc.SGHT
$76.05M
-4.4%
AVITA Medical, Inc.RCEL
$72.40M
+20.6%

Gross Margin (Latest Quarter)

MaxCyte, Inc.MXCT
92.4%
+16.1pp
Sight Sciences, Inc.SGHT
86.4%
+2.5pp
TriSalus Life Sciences, Inc.TLSI
83.5%
-2.8pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
SGHT$318.29M-6.8-61.6%35.0%
PROF$240.41M-6.0-86.8%0.7%
RPID$182.61M-4.1-73.9%28.6%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-6.8%
Growth Under Pressure
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
75%
Volatile Cash Flow

Research & Insights

Next earnings:Feb 4, 2026
|
EPS:-$0.11
|
Revenue:$100.86M
Reports
All Years
  • Form 10-Q - Q1 2026

    Period End: Sep 30, 2025|Filed: Nov 5, 2025|
    Revenue: $93.94M-7.5%
    |
    EPS: $-0.18+355.7%
    Miss
  • Form 10-K - FY 2025

    Period End: Jun 30, 2025|Filed: Aug 28, 2025|
    Revenue: $458.51M+2.7%
    |
    EPS: $-0.02+90.3%
    Miss
  • Form 10-Q - Q3 2025

    Period End: Mar 31, 2025|Filed: May 2, 2025|
    Revenue: $113.24M+12.0%
    |
    EPS: $-0.01-80.3%
    Beat
  • Form 10-Q - Q2 2025

    Period End: Dec 31, 2024|Filed: Feb 5, 2025|
    Revenue: $116.17M+8.3%
    |
    EPS: $0.03-125.4%
    Beat
  • Form 10-Q - Q1 2025

    Period End: Sep 30, 2024|Filed: Nov 6, 2024|
    Revenue: $101.55M-2.3%
    |
    EPS: $-0.04+28.7%
    Beat
  • Form 10-K - FY 2024

    Period End: Jun 30, 2024|Filed: Sep 19, 2024|
    Revenue: $446.55M-0.2%
    |
    EPS: $-0.16-63.6%
    Miss
  • Form 10-Q - Q3 2024

    Period End: Mar 31, 2024|Filed: May 8, 2024|
    Revenue: $101.13M-14.3%
    |
    EPS: $-0.06-1114.3%
    Miss
  • Form 10-Q - Q2 2024

    Period End: Dec 31, 2023|Filed: Feb 7, 2024|
    Revenue: $107.24M-6.6%
    |
    EPS: $-0.10+397.0%
    Miss